Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rohto® Hydra
- Development stage
- Unknown
- Lead developer
- Rohto Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Rohto® Hydra is a menthol-containing eyedrop developed by Rohto Pharmaceutical Co., Ltd. It is designed for topical ophthalmic application to alleviate symptoms associated with dry eye. The active ingredient, menthol, functions as a potent agonist of TRPM8, a corneal cold thermoreceptor, which is believed to play a role in dry eye symptoms.
- Brand names
- Rohto® Hydra
02
Targets
TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on Rohto® Hydra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rohto® Hydra.